Purpose
Although several studies have suggested that osteoporosis is common in survivors of gastric cancer (GC), no study to date has directly assessed the risk for osteoporosis in GC survivors compared to matched controls. Thus, we aimed to investigate the relative risk for osteoporosis in survivors of GC compared to general population.
Materials and Methods
We used the Korea National Health and Nutrition Examination Survey data (2008-2011). Patients with a history of GC (n=94) were defined as case among 8,142 individuals over 50 years old who were evaluated by dual-energy X-ray absorptiometry. Controls (n=470) were matched to cases by age and sex in a 1:5 ratio. Osteopenia (–2.5 < T-score < –1.0) and osteoporosis (T-score ≤ –2.5) were defined.
Results
The prevalence of osteoporosis in GC survivors was 30.2%, which was significantly greater than that of controls (19.7%). In total, GC survivors had a 3.7-fold increased risk for osteoporosis compared to controls (p=0.021). In addition, the risk for osteoporosis of the total proximal femur total (TF) and femur neck (FN) was significantly increased among GC survivors compared to controls (adjusted relative risk, 4.64; 95% confidence interval, 1.16 to 18.6 in TF and adjusted relative risk, 3.58; 95% confidence interval, 1.19 to 10.8 in FN). Furthermore, we found sub-optimal daily calcium intake and mean serum levels of 25-hydroxy-vitamin D in both groups.
Conclusion
GC survivors are at significantly increased risk for osteoporosis, especially in the femur. Clinically, our finding supports the importance of screening bone health and adequate nutrient supplementation in survivors of GC.
Citations
Citations to this article as recorded by
Senolytic treatment alleviates doxorubicin‐induced chemobrain Vivekananda Budamagunta, Ashok Kumar, Asha Rani, Sahana Manohar Sindhu, Yang Yang, Daohong Zhou, Thomas C. Foster Aging Cell.2024;[Epub] CrossRef
Association between Gastric Cancer and Osteoporosis: A Longitudinal Follow-Up Study Using a National Health Sample Cohort Kyeong Min Han, Mi Jung Kwon, Joo-Hee Kim, Ji Hee Kim, Woo Jin Bang, Hyo Geun Choi, Dae Myoung Yoo, Na-Eun Lee, Nan Young Kim, Ho Suk Kang Cancers.2024; 16(13): 2291. CrossRef
Preoperative abnormal bone mineral density as a prognostic indicator in patients undergoing gastrectomy for gastric cancer: A cohort study Soomin An, Wankyu Eo Medicine.2024; 103(21): e38251. CrossRef
The risk of osteoporotic fracture in gastric cancer survivors: total gastrectomy versus subtotal gastrectomy versus endoscopic treatment HyunJin Oh, Byung-Ho Yoon, Jung-Wee Park, Ye Jhin Jeon, Bit-Na Yoo, Jean Kyung Bak, Yong-Chan Ha, Young-Kyun Lee Gastric Cancer.2023; 26(5): 814. CrossRef
Factors Associated with Dietary Habit Changes in Korean Stomach Cancer Survivors after Cancer Treatment Junhee Park, Jiyoung Kim, Dong Wook Shin, Jinyoung Shin, Belong Cho, Yun-Mi Song Nutrients.2023; 15(14): 3268. CrossRef
Bone Fragility in Gastrointestinal Disorders Daniela Merlotti, Christian Mingiano, Roberto Valenti, Guido Cavati, Marco Calabrese, Filippo Pirrotta, Simone Bianciardi, Alberto Palazzuoli, Luigi Gennari International Journal of Molecular Sciences.2022; 23(5): 2713. CrossRef
Vitamin D—The Nutritional Status of Post-Gastrectomy Gastric Cancer Patients—Systematic Review Tomasz Muszyński, Karina Polak, Aleksandra Frątczak, Bartosz Miziołek, Beata Bergler-Czop, Antoni Szczepanik Nutrients.2022; 14(13): 2712. CrossRef
Bone Loss in Patients with Pancreatic Neuroendocrine Tumors He Tong, Miaomiao Wang, Jingjing Liu, Chuangen Guo, Zhongqiu Wang, Jianhua Wang, Xiao Chen Journal of Clinical Medicine.2022; 11(22): 6701. CrossRef
The risk of osteoporotic fractures after gastrectomy: Findings from the Korean national sample cohort database (2002-2019) Il Yun, Kyungduk Hurh, Sung Hoon Jeong, Eun-Cheol Park, Sung-In Jang Frontiers in Oncology.2022;[Epub] CrossRef
Incidence and risk factors of osteoporotic status in outpatients who underwent gastrectomy for gastric cancer Tsutomu Namikawa, Keiichiro Yokota, Jun Iwabu, Masaya Munekage, Sunao Uemura, Shigehiro Tsujii, Hiromichi Maeda, Hiroyuki Kitagawa, Takashi Karashima, Masamitsu Kumon, Keiji Inoue, Michiya Kobayashi, Kazuhiro Hanazaki JGH Open.2020; 4(5): 903. CrossRef
Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review) Leon Fisher, Alexander Fisher, Paul N Smith Journal of Clinical Medicine.2020; 9(10): 3253. CrossRef
Increased Risk of Osteoporotic Fracture in Postgastrectomy Gastric Cancer Survivors Compared With Matched Controls: A Nationwide Cohort Study in Korea Dong Wook Shin, Beomseok Suh, Hyunsun Lim, Yun-Suhk Suh, Yoon Jin Choi, Su-Min Jeong, Jae Moon Yun, Sun Ok Song, Youngmin Park American Journal of Gastroenterology.2019; 114(11): 1735. CrossRef
PURPOSE Vitamin D3 was shown to arrest the growth of acute myelogenous leukemic cells and transforming growth factor- B1 (TGF- B1) was reported to be involved in the mechanism of vitamin D3. We studied the growth inhibitory effect of 1,25(OH)2-vitamin D3(C) and its analogue (EB1089) in leukemic cell lines and the changes in the secretion or the activation of TGF-B1 in the supernatant and the status of TGF-B1 type II receptor. MATERIALS AND METHODS Growth inhibition by vitamin D3 and TGF-B1 in 5 leukemic cell lines (HEL, HL-60, U937, KG-1, K562) were assessed with clonogenic and [3H]thymidine assay respectively. TGF-B type II receptor status was examined by Southern and Northern blotting. The concentrations of TGF- B1 in the supernatant were quantitated by enzyme immunoassay. RESULTS The growth of HEL, HL-60, U937 were inhibited in a dose-dependent fashion by both C and EB1089, more markedly by the latter. Anti-TGF-B neutralizing antibody partially reversed the growth inhibition. TGF-B1 markedly inhibited the growth of HEL, U937, KG-1, SNU-16 dose dependently while HL-60 and K562 showed no growth inhibition. HEL secreted latent TGF- 1 and HL-60 activated latent TGF- B1 or secreted active TGF-B1 irrespective of the treatment with vitamin D3. In U937, vitamin D3 increased the concentration of both active and latent TGF-B1. Deletion or abnormal expression of TGF- B type II receptor gene was not found in the 5 cell lines examined. CONCLUSION Vitamin D3 has various pattern of growth inhibition in acute myelogenous leukemia and inhibits the growth of some cell lines by secretion or activation of TGF-B1. Abnormality of TGF-B type II receptor DNA or mRNA seems to be rare.